Abbott Laboratories (ABT)

75.00
0.25 0.33
NYSE : Health Technology
Prev Close 75.25
Open 75.16
Day Low/High 74.72 / 75.57
52 Wk Low/High 56.81 / 75.40
Volume 4.50M
Avg Volume 6.56M
Exchange NYSE
Shares Outstanding 1.76B
Market Cap 132.16B
P/E Ratio 167.22
Div & Yield 1.28 (1.57%)

Latest News

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Weekly Roundup

Markets pulled back this week following a strong January.

Weekly Roundup

It was a big week for earnings and Jerome Powell's Fed.

7 Best Investment Apps for Your Portfolio in 2019

7 Best Investment Apps for Your Portfolio in 2019

These mobile investment apps can get you up and trading fast, sometimes with no trading fees.

Weekly Roundup

It was another volatile week on Wall Street.

Shares of Abbott Laboratories Poised for Upside Breakout

Shares of Abbott Laboratories Poised for Upside Breakout

ABT is pointed up after trading in a choppy range since October.

Caterpillar, PG&E, Nio: 'Mad Money' Lightning Round

Caterpillar, PG&E, Nio: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Caterpillar, PG&E, Nio, Visa, Tenneco and more.

Hedge Fund Hooligans: Cramer's 'Mad Money' Recap (Wednesday 1/23/19)

Hedge Fund Hooligans: Cramer's 'Mad Money' Recap (Wednesday 1/23/19)

Jim Cramer says these giant hedge funds treat stocks like a plaything, and individual investors can lose out.

Abbott Labs Falls After Solid Earnings and Dividend Raise, Revenue Miss

Abbott Labs Falls After Solid Earnings and Dividend Raise, Revenue Miss

Abbott Labs has a good quarter and lifts its dividend but the stock slips.

Dow Rises as Wall Street Weighs Strong Earnings, Global Growth Concerns

Dow Rises as Wall Street Weighs Strong Earnings, Global Growth Concerns

The Dow Jones Industrial Average closed higher after solid earnings from several bellwethers helped to ease growth worries.

Abbott's Quarterly Results Show the Company Is Poised for More Growth in 2019

Abbott's fourth-quarter results capped off a terrific 2018.

Video: Jim's Daily Rundown for Wednesday

Jim discusses what United Technologies' results mean for Honeywell, Abbott and Comcast earnings, his discussion with Viacom CEO Robert Bakish, how members need to view and attack this market environment and more!

An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon

An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon

Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.

Abbott Reports 2018 Results And Issues Strong Forecast For 2019

Abbott Reports 2018 Results And Issues Strong Forecast For 2019

- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent

IBM, Procter & Gamble, Ford, Comcast and Mariano Rivera - 5 Things You Must Know

IBM, Procter & Gamble, Ford, Comcast and Mariano Rivera - 5 Things You Must Know

U.S. stock futures rise following the previous session's sharp selloff amid fears of a slowing global economy; IBM jumps as fourth-quarter earnings and guidance top estimates; Procter & Gamble, Ford and Comcast report earnings Wednesday.

Abbott Laboratories Expected to Earn 81 cents a Share

Abbott Laboratories Expected to Earn 81 cents a Share

Abbott Laboratories revenue expected to rise 3% to $7.8 billion.

Video: Jim's Daily Rundown for Tuesday

Jim discusses Johnson & Johnson's quarter, recaps Schlumberger's quarter, what he's looking for when Comcast and Abbott Labs report earnings, and more!

Abbott Offers A New Option For Physicians Treating Patients With Atrial Fibrillation

Abbott Offers A New Option For Physicians Treating Patients With Atrial Fibrillation

With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.

Weekly Roundup

U.S. markets pressed higher this week as earnings season got underway and on anticipation of a trade deal with China.

Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy

Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy

The kick will come from the Chinese capitulating because their economy is so weak.

Japanese Red Cross Society Selects Abbott Technology To Screen Country's Blood And Plasma Supply

Japanese Red Cross Society Selects Abbott Technology To Screen Country's Blood And Plasma Supply

LONG-TERM AGREEMENT BETWEEN JAPANESE RED CROSS SOCIETY AND ABBOTT BRINGS TOGETHER TWO GLOBAL LEADERS IN BLOOD AND PLASMA SCREENING, HELPING ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY ACROSS JAPAN

Abbott To Acquire Cephea Valve Technologies, Inc.

Abbott To Acquire Cephea Valve Technologies, Inc.

Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment

FDA Approves World's First Device For Treatment Of Premature Babies And Newborns With An Opening In Their Hearts (a Common Congenital Defect)

FDA Approves World's First Device For Treatment Of Premature Babies And Newborns With An Opening In Their Hearts (a Common Congenital Defect)

- First and only minimally invasive, transcatheter treatment specifically approved for premature babies with a patent ductus, a life-threatening opening in their heart

Weekly Roundup

The Dow, S&P 500 and Nasdaq all finished higher this week.

Abbott And "Malaria No More" Work Together To End Malaria In Odisha, India

Abbott And "Malaria No More" Work Together To End Malaria In Odisha, India

- Abbott to supply rapid diagnostic tests critical for malaria detection and surveillance, technical expertise and funding support

Keep These Themes In Mind

They continue to work in this market and we believe can drive growth longer-term.

New Favorites for 2019 from Last Year's Top Stock Pickers

New Favorites for 2019 from Last Year's Top Stock Pickers

Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.

TheStreet Quant Rating: A- (Buy)